

RESEARCH

Open Access



Haemodynamic determinants of quality of life in chronic heart failure

Serlie Fatrin^{1†}, Nduka C. Okwose^{1,3†}, Kristian Bailey², Lazar Velicki⁴, Dejana Popovic⁵, Arsen Ristic⁵, Petar M. Seferovic⁵, Guy A. MacGowan^{1,2} and Djordje G. Jakovljevic^{1,3*}

Abstract

Background: Heart failure patients demonstrate reduced functional capacity, hemodynamic function, and quality of life (QOL) which are associated with high mortality and morbidity rate. The aim of the present study was to assess the relationship between functional capacity, hemodynamic response to exercise and QOL in chronic heart failure.

Methods: A single-centre prospective study recruited 42 chronic heart failure patients (11 females, mean age 60 ± 10 years) with reduced left ventricular ejection fraction ($LVEF = 23 \pm 7\%$). All participants completed a maximal graded cardiopulmonary exercise test with non-invasive hemodynamic (bioreactance) monitoring. QOL was assessed using Minnesota Living with Heart Failure Questionnaire.

Results: The average value of QOL score was 40 ± 23 . There was a significant negative relationship between the QOL and peak O_2 consumption ($r = -0.50, p \leq 0.01$). No significant relationship between the QOL and selected exercise hemodynamic measures was found, including peak exercise cardiac power output ($r = 0.15, p = 0.34$), cardiac output ($r = 0.22, p = 0.15$), and mean arterial blood pressure ($r = -0.08, p = 0.60$).

Conclusion: Peak O_2 consumption, but not hemodynamic response to exercise, is a significant determinant of QOL in chronic heart failure patients.

Keywords: Heart failure, Quality of life, Exercise haemodynamics

Introduction

Exercise intolerance is a clinical hallmark of chronic heart failure. Reduced cardiac output and oxygen extraction are main underlying pathophysiological mechanisms explaining exercise intolerance in chronic heart failure [1–3]. Functional capacity (represented by peak exercise oxygen consumption) and hemodynamic response to exercise (peak exercise cardiac output and cardiac power

output) are strong determinants of prognosis and can be used to improve risk stratification in chronic heart failure [4, 5]. Reduced functional capacity and cardiac function are major causes of morbidity and mortality in chronic heart failure [6].

Patients with chronic heart failure demonstrate significantly lower Quality of Life (QOL) in comparison with other chronic conditions [7]. Improvement of QOL is an important end point in clinical and research practice [8, 9]. Despite this, limited number of studies have attempted to identify clinical and physiological determinants of QOL in chronic heart failure. In particular, association between hemodynamic function during exercise represented by peak cardiac power output, a marker of overall function and pumping capability of the heart [4], has not been evaluated. Therefore, the aim of the present

[†]Serlie Fatrin and Nduka C. Okwose: Joint first authors

*Correspondence: djordje.jakovljevic@newcastle.ac.uk

¹ Cardiovascular Research Theme, Translational and Clinical, and Biosciences Research Institutes, Medical School, Faculty of Medical Sciences, Newcastle University, William Leech Building 4th Floor, Framlington Place, Newcastle upon Tyne NE2 4HH, UK

Full list of author information is available at the end of the article



study was to assess functional capacity and hemodynamic response to exercise in chronic heart failure and determine their relationship with QOL.

Methods

A prospective, single-centre, cross-sectional study was performed to assess functional capacity, hemodynamic response to exercise in chronic heart failure patients. Quality of life was also assessed as detailed below. A total of 42 patients with stable chronic heart failure due to reduced left ventricular ejection fraction were recruited into the study. Patients were additionally screened to ensure that they met study inclusion criteria, which included heart failure due to reduced left ventricular ejection fraction (LVEF < 40%), NYHA functional class II and III, age 50 years or more, clinically stable (on optimal medication, no hospitalisation, or any acute event of worsening heart failure) for at least 6 weeks prior to the study, and an ability to perform maximal graded cardiopulmonary exercise stress testing.

All participants were instructed not to eat two hours before the visit to the clinical research facility where assessment procedures were undertaken. Participants were also instructed not to drink alcohol or caffeine on the day of assessment. Eligible participants signed an informed, written consent and all study procedures were in accordance with the Declaration of Helsinki and meets international ethical standards [10]. The study was approved by the research ethics committee of the National Health Service Northeast England—Tyne and Wear South, and local Research and Development department.

Upon arrival at the Clinical Research Facility, study participants' anthropometric measurements (body weight and height) were obtained. Participants also answered a standardized health screening questionnaire according to the Standard Operating Procedure of the Clinical Exercise Laboratory. All patients completed a maximal graded cardiopulmonary exercise test using a semi-recumbent, electromagnetically controlled cycle ergometer (Corival, Lode & Groningen, Netherland) with non-invasive gas exchange (Cortex metalyser 3B, Leipzig, Germany) and bioreactance method for haemodynamic monitoring (NICOM[®], Cheetah Medical, USA) [11]. Exercise stress test was carried out according to recommendations from the American College of Sports Medicine and was supervised by a consultant cardiologist with special interest in heart failure who was part of the research team. Before exercise testing, implanted devices were turned off for patients with ICD. Test protocol included a warm-up for 3 min at 20 W and then load was increased by 10 W per minute until maximum exertion was achieved. The cadence of 60–70 revolutions per minute was maintained

throughout the test. Hemodynamic (cardiac output and stroke volume), arterial blood pressure, electrocardiogram and gas exchange measurements were performed at rest and during exercise test. Standardised Borg scale (0–20) was used to indicate level of exertion [12] Maximal effort was achieved if: (1) the participant could no longer cycle at 60–70 revolutions per minute, (2) respiratory exchange ratio of 1.10 or higher, (3) oxygen consumption does no further increase despite increase in workload, or (4) $\geq 90\%$ of maximum age adjusted heart rate. The test was terminated at maximum exertion or if the participant had requested to terminate the exercise test earlier.

Hemodynamic variables measured during exercise stress test were heart rate, systolic and diastolic blood pressure, stroke volume, which are then used to calculate cardiac output, mean arterial blood pressure, and cardiac power output. Cardiac power output was calculated using the following formula:

$$\text{CPO} = (\text{CO} \times \text{MAP}) \times K$$

where CPO is cardiac power output, CO is cardiac output, MAP is mean arterial blood pressure and $K = 2.22 \times 10^{-3}$, is the conversion factor into watts [13].

Non-invasive gas exchange measurement allowed determination of peak oxygen consumption and subsequent calculation of the arteriovenous oxygen difference using measured oxygen consumption and cardiac output. Minnesota Living with Heart Failure (MLHF) Questionnaire was used to assess heart failure related QOL.

All results are expressed as mean \pm SD unless stated otherwise. Before SPSS analysis, the data were screened for univariate and multivariate outliers using Z-distribution cut-offs and Mahalanobis distance test. Kolmogorov Smirnov test was used to assess normality. Baseline haemodynamic measures and response to exercise were compared between patients and healthy controls using independent sample t-test. Pearson's coefficient of correlation (r) was used to assess the relationship between quality of life and measures of hemodynamic response to stress exercise in chronic heart failure. A p value < 0.05 was considered statistically significant. Statistical analysis was carried out using SPSS version 24.0 (SPSS Inc, Chicago, IL).

Results

Demographic, clinical, and physical characteristics of patients are indicated in Table 1.

There was a higher proportion of males ($n = 31$, 74%) and patients were categorised into NYHA functional class II ($n = 19$) or III ($n = 23$). Metabolic and haemodynamic measures at rest and peak exercise are presented in Table 2. Pearson's coefficient of correlation was used

Table 1 Participants’ demographic and clinical characteristics (n = 42)

Age (years)	60 ± 10
Male/female (%)	74/26
Weight (kg)	88 ± 15
Height (m)	1.73 ± 0.07
BMI (kg/m ²)	29 ± 4
Functional class (NYHA) II/III	19/23
LVEF (%)	23 ± 7
MLHF	40 ± 23
Aetiology (IHD/DCM/Others)	22/14/6
AF	14
ICD	19
<i>Medication; n (%)</i>	
ACE inhibitors	27 (64)
β-blockers	41 (98)
ARBs	9 (21)
Diuretics	33 (78)
MRA	27 (64)
Anti-arrhythmic	14 (33)
NSAID/analgesic	12 (28)
Antiplatelet/anticoagulant	17 (40)
ARNI	4 (9)

ACE angiotensin converting enzyme, AF atrial fibrillation, ARB angiotensin receptor blockers, ARNI angiotensin receptor neprilysin inhibitor, DCM dilated cardiomyopathy, IHD ischaemic heart disease, LVEF left ventricular ejection fraction, MLHF Minnesota living with heart failure, MRA mineralocorticoid receptor antagonist, NYHA New York Heart Association, NSAID non-steroid anti-inflammatory drugs

Table 2 Metabolic and haemodynamic measures at rest and peak exercise (n = 42)

Parameter	Rest	Peak exercise
Oxygen consumption (ml/kg/min)	4.1 ± 1.2	14.1 ± 4.7
Systolic blood pressure (mmHg)	109 ± 19	133.6 ± 32.6
Diastolic blood pressure (mmHg)	69 ± 10	74.4 ± 13.2
Mean arterial blood pressure (mmHg)	83 ± 12	88 ± 22
Stroke volume (ml/beat)	87 ± 23	127 ± 35
Cardiac output (l/min)	6.0 ± 1.3	13.9 ± 3.6
Cardiac power output (watts)	1.1 ± 0.3	2.9 ± 0.8
Heart rate (beats/min)	70 ± 9	106 ± 21
Arteriovenous oxygen difference (ml/100 ml)	6.4 ± 2.7	9.2 ± 3.3

to assess the strength of the relationship between hemodynamic and metabolic response to exercise and QOL. There was a significant negative relationship between QOL score and peak oxygen consumption ($r = -0.50$, $p < 0.01$, Fig. 1A). Peak exercise arteriovenous oxygen difference was also significantly related to QOL ($r = -0.36$, $p = 0.02$, Fig. 1B). There was no relationship between

QOL score and peak exercise cardiac output, cardiac power output Fig. 1C–D), or mean arterial blood pressure ($p > 0.05$).


Discussion

The major findings of the present study suggest that in chronic heart failure, QOL is significantly correlated with peak oxygen consumption mediated primarily via improved arterio-venous oxygen difference (increased skeletal muscle oxygen uptake) but not exercise hemodynamic measures such as cardiac power output, cardiac output, or mean arterial blood pressure. These findings provide better understanding of determinants of QOL in chronic heart failure, further suggesting that impaired cardiac function may not consequently lead to reduced quality of life. On the other hand, patients with higher functional capacity (peak O₂ consumption) will likely have better QOL as demonstrated with lower scores on Minnesota Living with Heart Failure quality of life questionnaire.

Cardiac power output has been proposed to be the best indicator of overall function and pumping capability as it accounts for both flow and pressure generating capacities of the heart [5, 14]. When compared to result of studies with age matched controls [5, 14], findings of the present study reaffirms that patients with chronic heart failure showed reduced cardiac function as represented by lower resting and peak exercise cardiac power output.

Reduced exercise capacity (i.e., lower peak exercise O₂ consumption) reported in the present study is consistent with previous studies [15–18] with reduced cardiac output and stroke volume being the main cardiac determinants responsible for lower exercise tolerance [19]. Although, being a strong prognostic marker in chronic heart failure, oxygen consumption is not only influenced by central (cardiac) but also by peripheral factors (skeletal muscle function), systemic inflammation, ageing, motivation to exercise, gender [1, 2]. Like the present study, previous reports have shown a lack of relationship between central haemodynamic measures and exercise tolerance [9, 20]. In contrast, exercise tolerance assessed using a series of self-paced corridor walk tests showed moderate correlations with cardiac index [20], thus questioning the assessment of cardiac output in heart failure patients using maximal tests performed in the laboratory which do not represent patients’ true capabilities.

Despite reduced peak oxygen consumption compared to healthy subjects, our results demonstrate a significant negative relationship between QOL score and peak oxygen consumption like other reports [21, 22]. Peripheral blood flow blood is a better determinant of exercise capacity. An increase in muscle oxygen extraction beyond submaximal exercise has a compensatory effect



on reduced cardiac output, to increase peak oxygen consumption [23–25]. Hence, we can infer that an increase in peak arterio-venous oxygen difference, but not cardiac output or cardiac power output is the reason for significant correlation between QOL and peak oxygen consumption.

Numerous instruments (questionnaires) have become available to measure patients’ health-related quality of life. However, disease-specific questionnaires such as Minnesota Living with Heart Failure is more sensitive to detecting changes than generic questionnaires [26]. In the present study the average score of MLHF quality of life questionnaire was 40, with range from 3 to 89, suggesting wide range of quality of life in the studied patients.

Quality of life is increasingly becoming one of the primary outcomes in clinical and research practice in heart failure. Pharmacological, surgical, and physiological interventions known to improve functional capacity are likely to lead to improved QOL in chronic heart failure, while those focusing in improving haemodynamic

function only may not necessarily lead to patient experience of better QOL.

The following limitations of the current study should be taken into consideration. Firstly, the number of patients recruited into the study was only moderate. Secondly, majority of patients were males with less than one third of patients were females. Lastly, this was a cross-sectional study which evaluated exercise capacity using only one method. Therefore, generalisability of the present study findings and its conclusions should be considered with caution.

In conclusion, patients with chronic heart failure demonstrate reduced functional capacity and overall cardiac function. Significant negative relationship between functional capacity and quality of life score suggests that peak exercise oxygen consumption mediated via increased skeletal muscle oxygen consumption is an important determinant of quality of life in chronic heart failure. In contrast, peak exercise central hemodynamic measures i.e., cardiac power output, cardiac output and mean arterial blood pressure were not significantly correlated with

quality-of-life score, indicating their limited capacity to reflect quality of life in patients with chronic heart failure.

Acknowledgements

The authors would like to thank the participants of the present study and the staff of the Clinical Research Facility, Royal Victoria Infirmary, Newcastle upon Tyne for their clinical and administrative support during the study.

Author contributions

DGJ, GAM: Study concept and design. DP, GAM: Study Supervision. KB and GAM, SF, DGJ, NCO: Acquisition of data. SF, AR: Data analysis and interpretation of data. SF and NCO: Drafting of the manuscript. DGJ, PMS, NCO, GAM, LV, AR, DP: Critical revision of the manuscript. DGJ acts as the guarantor and take responsibility for the content of the manuscript, including the data and analysis. All authors read and approved the final manuscript.

Funding

This study is supported by Research Councils' UK Centre for Ageing and Vitality at Newcastle University [Grant Number L016354]. NO, LV, DP, AR, GAM, and DGJ are supported by the European Horizon 2020 Research and Innovation Programme under the grant agreement number 952603. The funding sources did not have a direct role in the design, collection, analysis, or interpretation of data, nor in the manuscript preparation, which is solely the remit of the author(s).

Availability of data and materials

All data generated or analysed during this study are included in this published article. Additional information will be made available upon reasonable request by the corresponding author.

Declarations

Ethics approval and consent to participate

The study was conducted in accordance with the Helsinki declaration and was approved by the UK National Health Service Research Ethics Committee of Northeast England—Tyne and Wear South, and local Research and Development department. All participants gave written informed consent before participation in the study.

Consent for publication

No personal information was used in the draft of this article.

Competing interests

The authors declare no competing interests.

Author details

¹Cardiovascular Research Theme, Translational and Clinical, and Biosciences Research Institutes, Medical School, Faculty of Medical Sciences, Newcastle University, William Leech Building 4th Floor, Framlington Place, Newcastle upon Tyne NE2 4HH, UK. ²Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK. ³Research Centre (CSELS), Institute for Health and Wellbeing, Faculty of Health and Life Sciences, Coventry University, Coventry, UK. ⁴Institute of Cardiovascular Diseases Vojvodina, University of Novi Sad, Novi Sad, Serbia. ⁵Department of Cardiology, Medical School, Clinical Centre of Serbia, University of Belgrade, Belgrade, Serbia.

Received: 2 June 2022 Accepted: 18 August 2022

Published online: 16 September 2022

References

1. van Wezenbeek J, Canada JM, Ravindra K, et al. Determinants of cardiorespiratory fitness in patients with heart failure across a wide range of ejection fractions. *Am J Cardiol*. 2019;125:76–81. <https://doi.org/10.1016/j.amjcard.2019.09.036>.
2. del Buono MG, Arena R, Borlaug BA, et al. Exercise intolerance in patients with heart failure: JACC state-of-the-art review. *J Am Coll Cardiol*. 2019;73:2209–25. <https://doi.org/10.1016/j.jacc.2019.01.072>.
3. Coats AJ, Adamopoulos S, Radaelli A, et al. Controlled trial of physical training in chronic heart failure. Exercise performance, hemodynamics, ventilation, and autonomic function. *Circulation*. 1992;85:2119–31. <https://doi.org/10.1161/01.CIR.85.6.2119>.
4. Williams SG, Cooke GA, Wright DJ, et al. Peak exercise cardiac power output: a direct indicator of cardiac function strongly predictive of prognosis in chronic heart failure. *Eur Heart J*. 2001;22:1496–503. <https://doi.org/10.1053/euhj.2000.2547>.
5. Lang CC, Karlin P, Haythe J, et al. Peak cardiac power output, measured noninvasively, is a powerful predictor of outcome in chronic heart failure. *Circ Heart Fail*. 2009;2:33–8. <https://doi.org/10.1161/CIRCHEARTFAILURE.108.798611>.
6. O'Connor CM, Whellan DJ, Lee KL, et al. Efficacy and safety of exercise training in patients with chronic heart failure. *JAMA*. 2009;301:1439. <https://doi.org/10.1001/jama.2009.454>.
7. Juenger J, Schellberg D, Kraemer S, et al. Health related quality of life in patients with congestive heart failure: comparison with other chronic diseases and relation to functional variables. *Heart*. 2002;87:235–41. <https://doi.org/10.1136/heart.87.3.235>.
8. Belardinelli R, Georgiou D, Cianci G, et al. Randomized, controlled trial of long-term moderate exercise training in chronic heart failure: effects on functional capacity, quality of life, and clinical outcome. *Circulation*. 1999;99:1173–82. <https://doi.org/10.1161/01.CIR.99.9.1173>.
9. Houghton AR, Harrison M, Cowley AJ, et al. Assessing exercise capacity, quality of life and haemodynamics in heart failure: do the tests tell us the same thing? *Eur J Heart Fail*. 2002;4:289–95. [https://doi.org/10.1016/S1388-9842\(01\)00236-7](https://doi.org/10.1016/S1388-9842(01)00236-7).
10. Harriss DJ, Macsween A, Atkinson G. Ethical standards in sport and exercise science research: 2020 update. *Int J Sports Med*. 2019;40:813–7. <https://doi.org/10.1055/a-1015-3123>.
11. Jones TW, Houghton D, Cassidy S, et al. Bioreactance is a reliable method for estimating cardiac output at rest and during exercise. *Br J Anaesth*. 2015;115:386–91. <https://doi.org/10.1093/bja/aeu560>.
12. Williams N. The Borg rating of perceived exertion (RPE) scale. *Occup Med*. 2017;67:404–5. <https://doi.org/10.1093/occmed/kqx063>.
13. Jakovljevic DG, Donovan G, Nunan D, et al. The effect of aerobic versus resistance exercise training on peak cardiac power output and physical functional capacity in patients with chronic heart failure. *Int J Cardiol*. 2010;145:526–8. <https://doi.org/10.1016/j.ijcard.2010.04.060>.
14. Jakovljevic DG, Seferovic PM, Nunan D, et al. Reproducibility of cardiac power output and other cardiopulmonary exercise indices in patients with chronic heart failure. *Clin Sci (London, England, 1979)*. 2012;122:175–81. <https://doi.org/10.1042/CS20110355>.
15. Fukuda T, Matsumoto A, Kurano M, et al. Cardiac output response to exercise in chronic cardiac failure patients: role of stroke volume. *Int Heart J*. 2012;53:293–8. <https://doi.org/10.1536/ihj.53.293>.
16. Sato T, Yoshihisa A, Kanno Y, et al. Cardiopulmonary exercise testing as prognostic indicators: comparisons among heart failure patients with reduced, mid-range and preserved ejection fraction. *Eur J Prev Cardiol*. 2017;24:1979–87. <https://doi.org/10.1177/2047487317739079>.
17. Corrà U, Mezzani A, Giordano A, et al. Peak oxygen consumption and prognosis in heart failure: 14 mL/kg/min is not a "gender-neutral" reference. *Int J Cardiol*. 2013;167:157–61. <https://doi.org/10.1016/j.ijcard.2011.12.055>.
18. Shimiäie J, Sherez J, Aviram G, et al. Determinants of effort intolerance in patients with heart failure: combined echocardiography and cardiopulmonary stress protocol. *JACC Heart Fail*. 2015;3:803–14. <https://doi.org/10.1016/j.jchf.2015.05.010>.
19. McCoy J, Bates M, Eggett C, et al. Pathophysiology of exercise intolerance in chronic diseases: the role of diminished cardiac performance in mitochondrial and heart failure patients. *Open Heart*. 2017. <https://doi.org/10.1136/openhrt-2017-000632>.
20. Cowley AJ, Fullwood LJ, Muller AF, et al. Exercise capability in heart failure: is cardiac output important after all? *Lancet*. 1991;337:771–3. [https://doi.org/10.1016/0140-6736\(91\)91381-4](https://doi.org/10.1016/0140-6736(91)91381-4).
21. Nogueira IDB, Servantes DM, Nogueira PAMS, et al. Correlation between quality of life and functional capacity in cardiac failure. *Arquivos brasileiros de cardiologia*. 2010;95:238–43.
22. Athanasopoulos LV, Dritsas A, Doll HA, et al. Comparative value of NYHA functional class and quality-of-life questionnaire scores in assessing heart

- failure. *J Cardiopulm Rehabil Prev*. 2010;30:101–5. <https://doi.org/10.1097/HCR.0b013e3181be7e47>.
23. Dhakal BP, Malhotra R, Murphy RM, et al. Mechanisms of exercise intolerance in heart failure with preserved ejection fraction: the role of abnormal peripheral oxygen extraction. *Circ Heart Fail*. 2015;8:286–94. <https://doi.org/10.1161/CIRCHEARTFAILURE.114.001825>.
 24. Schmidt T, Bjarnason-Wehrens B, Mommertz S, et al. Changes in total cardiac output and oxygen extraction during exercise in patients supported with an HVAD left ventricular assist device. *Artif Organs*. 2018;42:686–94. <https://doi.org/10.1111/aor.13102>.
 25. Sullivan MJ, Higginbotham MB, Cobb FR. Exercise training in patients with chronic heart failure delays ventilatory anaerobic threshold and improves submaximal exercise performance. *Circulation*. 1989;79:324–9. <https://doi.org/10.1161/01.CIR.79.2.324>.
 26. Riegel B, Moser DK, Glaser D, et al. The Minnesota living with heart failure questionnaire: sensitivity to differences and responsiveness to intervention intensity in a clinical population. *Nurs Res*. 2002;51:209–18. <https://doi.org/10.1097/00006199-200207000-00001>.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

